Wave Life Sciences regained full rights to WVE-006 from GSK for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. Wave plans to accelerate the registrational strategy and pursue an accelerated FDA approval pathway, with regulatory feedback expected mid-2026. Clinical trial data from the RestorAATion-2 trial is on track for Q1 2026. WVE stock rose 4.48% on the announcement.

The article highlights three stocks showing potential for upside momentum in 2026 based on golden cross technical signals and fundamental analysis: Sun Communities, Darling Ingredients, and Wave Life Sciences.

Wave Life Sciences announced a public offering of 15,789,475 ordinary shares and pre-funded warrants, expecting to raise approximately $350 million to support its RNA medicines platform and clinical programs.

Wave Life Sciences experienced a significant stock surge following positive Phase 1 clinical study results for its obesity drug candidate WVE-007, with analysts upgrading price targets and recommendations.

Wave Life Sciences saw a massive stock surge after reporting promising phase 1 clinical trial results for its investigational weight loss drug WVE-007, which demonstrated significant body fat reduction and potential competitive advantages over existing GLP-1 drugs.

Wave Life Sciences presented preclinical data for WVE-007, a novel RNA medicine targeting obesity by silencing INHBE mRNA. Preclinical studies showed potential for fat loss while preserving muscle mass, with promising initial clinical trial results demonstrating significant Activin E reduction.

Wave Life Sciences reported significant Activin E reductions of up to 85% in its INLIGHT clinical trial for obesity treatment, with WVE-007 showing promising results in fat loss potential and safety profile across multiple dose cohorts.

Wave Life Sciences reported a challenging Q2 2025, with revenue declining 55.8% to $8.7 million and a net loss of $50.5 million. Despite financial setbacks, the company continues to advance its RNA-based medicine pipeline across multiple therapeutic areas.

Elkedonia, a French-Belgian startup, has raised €11.25 million in seed funding to develop novel, fast-acting, non-addictive, and non-hallucinogenic treatments for treatment-resistant depression and other neuropsychiatric disorders. The company's approach targets the intracellular protein Elk1, which plays a key role in brain reward circuits and neuroplasticity.

Elkedonia, a new startup company, has closed an EUR 11.25 million seed funding round to develop therapeutic agents to treat depression and other neuropsychiatric conditions. The company is leveraging research from Sorbonne University and industry experts from Argobio.

The article discusses the prevalence and impact of rare genetic disorders, which affect over 350 million people worldwide. It highlights the challenges in treating these conditions, including limited treatment options and underfunding for research. The article also provides an overview of the market analysis for various rare genetic disorders, including Usher Syndrome, Alport Syndrome, Menkes Disease, and others.

Wave Life Sciences announced updates on its growing pipeline, including new preclinical data for its GalNAc-siRNA approach for obesity (WVE-007) and the introduction of three new GalNAc-RNA editing programs targeting cardiometabolic diseases.